Trade AtriCure Inc - ATRC CFD

AtriCure Company profile

About AtriCure Inc.

AtriCure, Inc. is a provider of technologies for the treatment of atrial fibrillation (Afib) and related conditions. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue, systems designed for the exclusion of the left atrial appendage, and devices designed to block pain by temporarily ablating peripheral nerves. These devices are developed and marketed to medical centers globally. Its ablation and left atrial appendage management (LAAM) products are used by physicians during both open-heart and minimally invasive procedures. Its products for open and minimally invasive ablation includes Isolator Synergy Clamp and Multifunctional Pens and Linear Ablation Devices. Its Product for open ablation are cryoICE Cryoablation System. Its product for minimally invasive ablation are EPi-Sense Guided Coagulation System with VisiTrax Technology. Its products for appendage management includes AtriClip System and LARIAT System.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, AtriCure Inc. revenues increased 33% to $274.3M. Net income totaled $50.2M vs. loss of $48.2M. Revenues reflect Appendage Management segment increase of 41% to $94.6M, Open-Heart Ablation segment increase of 25% to $93.9M, United States segment increase of 35% to $229.1M, Europe segment increase of 20% to $27.9M. Net Income reflects Int exp on Financial Lease Liabiliti decrease of 6% to $792K (expense).

Equity composition

Common Stock $.001 Par, 045/11, 90M auth., 15,953,682 issd. Insiders & Strategic holders own 20.47%. IPO8/5/05, 4M shares @ $12 per share by UBS Investment Bank, Thomas Weisel Partners LLC, Piper Jaffray and AG Edwards.